Millennium Management Llc Purchases 5,731 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc bought 5,731 shares of the business’s stock in a transaction on Thursday, March 26th. The shares were acquired at an average cost of $28.62 per share, with a total value of $164,021.22. Following the purchase, the insider owned 131,370 shares of the company’s stock, valued at $3,759,809.40. The trade was a 4.56% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $26.61 per share, with a total value of $407,691.81.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc bought 6,175 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $34.49 per share, with a total value of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc bought 6,005 shares of Sensei Biotherapeutics stock. The shares were acquired at an average cost of $28.16 per share, with a total value of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Stock Up 3.1%

SNSE stock opened at $20.43 on Friday. The business has a fifty day moving average of $28.89 and a two-hundred day moving average of $17.87. The stock has a market cap of $27.38 million, a price-to-earnings ratio of -0.14 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a 52-week low of $5.25 and a 52-week high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($130.83). As a group, sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SNSE. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Leerink Partners began coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective for the company. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $40.00.

Key Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.